Figure 3. Prevalence of participants on ART affected by HGRT (RT
and PI gene), and the number of fully active ARVs and CPE score before
and after adjusting for HGRT in cases with and without CVE
Panel (A) shows the prevalence of ART regimens affected by HGRT in
participants with and without CVE. Panel (B) shows the number of fully
active drugs in the current ART regimen after adjusting for HGRT;
participants with CVE moved from 3 drugs (3-3) to 2 drugs (1-3;
p<0.001, D 0.922) versus 3 (3-3) to 3 drugs (2-3;
p<0.001, D 0.469) in participants without CVE, despite the
difference being not statistically relevant between groups (p=0.242).
Panel (C) shows mean changes from CPE score to HGRT-adjusted CPE score
in participants without and with CVE; participants with CVE moved from 7
(7-8) to 6 (4-7; p<0.001, D 0.850) versus a decrease from 7
(7-8) to 7 (6-8; p<0.001, D 0.449) in participants without CVE
and the difference in the median HGRT-adjusted CPE between groups was
statistically significant (p=0.038; Fig.3). Legend: ARVs, antiretroviral
drugs; HGRT, historical cumulative genotype resistance test; RT, reverse
transcriptase gene; PI, protease gene; CVE, cerebrospinal fluid viral
escape; ART, antiretroviral therapy; CPE, Central nervous system
effectiveness penetration score.